1st Quarter - Report · 2026

Filing UUID: 04b16bc3-95ee-4cba-b676-9bba1e748a61
Type: Q1 — 1st Quarter - Report
Period: first_quarter
Year: 2026
Posted: 2026-04-16 20:40:43
Income (reported): $40,000
Expenses (reported): —
Filing document: Open on lda.senate.gov

Registrant (lobbying firm)

CAPITOL COUNSEL LLC

Government affairs.

Contact: TRACEY A. GRAY
Phone: +1 202-861-3200
Address: zip:20005, city:Washington, state:DC, street:700 13th Street NW, 2nd Floor

Client

LUNDBECK PHARMACEUTICALS LLC

Specialty and Central Nervous System Bio-pharmaceutical manufacturing.

State: IL
Country: US
Effective date: 2022-01-01

Issues lobbied + lobbyists

`HCR` — Health Issues

Issues regarding Pill Penalty caused by the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA. PBM Issues, including H.R./S._Modernizing and Ensuring PBM Accountability Act.

Lobbyists: SHANNON FINLEY; ANN JABLON; JEFFREY CARROLL; LUKE HATZIS; JOHN MARTIN; mr CHARLES PATRICK MICHAELS; JOSEPH EANNELLO; KAREN STONE

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

`MMM` — Medicare/Medicaid

Issues regarding the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA. PBM Issues, including H.R./S._ Modernizing and Ensuring PBM Accountability Act and H.R./S._Lower Costs, More Transparency Act. Issues regarding effective solutions for improving clinical care in long-term care settings and other solutions aimed at improving the diagnosis and management of neuropsychiatric symptoms (NPS) in dementia. Orphan Drug Provisions included in HR.1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21. 340 program issues.